Sources say Sanofi's board will mull higher bid for Genzyme

09/30/2010 | Wall Street Journal, The

Sanofi-Aventis' board will hold a meeting in a few days to decide if it will increase its $69-per-share offer for Genzyme, sources said. Most directors on Sanofi's board believe that increasing the offer will grant the company access to Genzyme's books and allow for due diligence. Meanwhile, a spokesman for the Paris-based company said Sanofi so far has stuck to its original offer of $18.5 billion in cash.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY